* Iteos Therapeutics Inc ITOS.OQ ITOS.O is expected
to show a
fall in quarterly revenue when it reports results on August 8
(estimated).
*
* Refinitiv's mean analyst estimate for Iteos Therapeutics
Inc is
for a loss of $1.03 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Iteos
Therapeutics Inc is $41, above its last closing price
of $13.46.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -1.00 -0.99 -0.44 Beat 55.8
Dec. 31 2023 0.33
Sep. 30 2022 0.11 0.10 0.03 Missed -69.2
Jun. 30 2022 1.13 1.20 0.15 Missed -87.5
Mar. 0.79 0.80 1.82 Beat 128.9
31 2022
Dec. 31 2021 1.84 1.28 4.89 Beat 282.6
Sep. 30 2021 6.09 4.95 1.86 Missed -62.4
Jun. 30 2021 -0.45 -0.41 -0.75 Missed -81.2
This summary was machine generated August 4 at 13:31 GMT. All
figures in US dollars unless otherwise stated